198 related articles for article (PubMed ID: 24258456)
1. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Tiseo M; Ippolito M; Scarlattei M; Spadaro P; Cosentino S; Latteri F; Ruffini L; Bartolotti M; Bortesi B; Fumarola C; Caffarra C; Cavazzoni A; Alfieri RR; Petronini PG; Bordonaro R; Bruzzi P; Ardizzoni A; Soto Parra HJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):299-307. PubMed ID: 24258456
[TBL] [Abstract][Full Text] [Related]
2. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
4. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
Kahraman D; Holstein A; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Dietlein M; Wolf J; Kobe C
Clin Nucl Med; 2012 Nov; 37(11):1058-64. PubMed ID: 23027207
[TBL] [Abstract][Full Text] [Related]
5. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
6. Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
Suleiman AA; Frechen S; Scheffler M; Zander T; Kahraman D; Kobe C; Wolf J; Nogova L; Fuhr U
J Thorac Oncol; 2015 Jan; 10(1):84-92. PubMed ID: 25226426
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.
Ma J; Wu X; Li J; Wang Z; Wang Y
J Investig Med; 2017 Jun; 65(5):935-941. PubMed ID: 28360035
[TBL] [Abstract][Full Text] [Related]
8. Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer.
Banna GL; Anile G; Russo G; Vigneri P; Castaing M; Nicolosi M; Strano S; Gieri S; Spina R; Patanè D; Calcara G; Fraggetta F; Marletta F; Stefano A; Ippolito M
Oncology; 2017; 92(1):39-47. PubMed ID: 27832654
[TBL] [Abstract][Full Text] [Related]
9. [¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.
Hachemi M; Couturier O; Vervueren L; Fosse P; Lacœuille F; Urban T; Hureaux J
PLoS One; 2014; 9(2):e87629. PubMed ID: 24505298
[TBL] [Abstract][Full Text] [Related]
10. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.
Benz MR; Herrmann K; Walter F; Garon EB; Reckamp KL; Figlin R; Phelps ME; Weber WA; Czernin J; Allen-Auerbach MS
J Nucl Med; 2011 Nov; 52(11):1684-1689. PubMed ID: 22045706
[TBL] [Abstract][Full Text] [Related]
11. Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.
Cook GJ; O'Brien ME; Siddique M; Chicklore S; Loi HY; Sharma B; Punwani R; Bassett P; Goh V; Chua S
Radiology; 2015 Sep; 276(3):883-93. PubMed ID: 25897473
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
Kobe C; Scheffler M; Holstein A; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Dietlein M; Wolf J; Kahraman D
Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1117-27. PubMed ID: 22526960
[TBL] [Abstract][Full Text] [Related]
13. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
14. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
[TBL] [Abstract][Full Text] [Related]
15. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
Zander T; Scheffler M; Nogova L; Kobe C; Engel-Riedel W; Hellmich M; Papachristou I; Toepelt K; Draube A; Heukamp L; Buettner R; Ko YD; Ullrich RT; Smit E; Boellaard R; Lammertsma AA; Hallek M; Jacobs AH; Schlesinger A; Schulte K; Querings S; Stoelben E; Neumaier B; Thomas RK; Dietlein M; Wolf J
J Clin Oncol; 2011 May; 29(13):1701-8. PubMed ID: 21422426
[TBL] [Abstract][Full Text] [Related]
16. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
[TBL] [Abstract][Full Text] [Related]
17. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
18. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
19. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.
Lee DH; Kim SK; Lee HY; Lee SY; Park SH; Kim HY; Kang KW; Han JY; Kim HT; Lee JS
J Thorac Oncol; 2009 Jul; 4(7):816-21. PubMed ID: 19487962
[TBL] [Abstract][Full Text] [Related]
20. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]